Rituximab effective in first-line CLL
In a pivotal phase III study, rituximab (Rituxan) in combination with standard chemotherapy significantly increased time to progression in patients with previously untreated chronic lymphocytic leukemia
BASEL, SwitzerlandIn a pivotal phase III study, rituximab (Rituxan) in combination with standard chemotherapy significantly increased time to progression in patients with previously untreated chronic lymphocytic leukemia, compared with chemotherapy alone.
In a press release, Roche, which markets the agent in Europe as MabThera, announced that the CLL8 trial, initiated by the German CLL study group, had reached its primary endpoint almost a year ahead of schedule.
The randomized international trial was conducted at 203 sites across 11 countries. It included 817 patients with CLL receiving first-line treatmenteither rituximab with fludarabine and cyclophosphamide or chemotherapy alone. The study aimed to show a 35% increase in progression-free survival with rituximab.
Data from the CLL8 study will be submitted for presentation at upcoming international scientific meetings, the company said.
Newsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
![“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.](/_next/image?url=https%3A%2F%2Fcdn.sanity.io%2Fimages%2F0vv8moc6%2Fcancernetwork%2F267879fc15a40ec8d3ed04d8ee9c1f044b49ee89-2990x1692.png%3Ffit%3Dcrop%26auto%3Dformat&w=3840&q=30 "“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.")
The Proper Ways to Identify and Use ADCs in Breast Cancer Subtypes
June 29th 2025Deciding when to use immunotherapy and how to utilize antibody-drug conjugates are complicated processes that require multidisciplinary collaboration to ensure that all patients with breast cancer receive appropriate and efficient care.
